AR035119A1 - Anticuerpos humanos antagonistas anti-htnfsf13b - Google Patents

Anticuerpos humanos antagonistas anti-htnfsf13b

Info

Publication number
AR035119A1
AR035119A1 ARP020103052A ARP020103052A AR035119A1 AR 035119 A1 AR035119 A1 AR 035119A1 AR P020103052 A ARP020103052 A AR P020103052A AR P020103052 A ARP020103052 A AR P020103052A AR 035119 A1 AR035119 A1 AR 035119A1
Authority
AR
Argentina
Prior art keywords
seq
polypeptide
tnfsf13b
htnfsf13b
lcvr
Prior art date
Application number
ARP020103052A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23213094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR035119(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR035119A1 publication Critical patent/AR035119A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen anticuerpos monoclonales humanos que se unen específicamente a polipéptidos TNFSF13b. Estos anticuerpos tienen una alta afinidad hacia hTNFSF13b (por ejemplo, KD = 10-8 M o inferior), una velocidad lenta de separación para la disociación de TNFSF13b (por ejemplo, Ksep = 10-3 s-1 o inferior) y neutralizan la actividad TNFSF13b in vitro e in vivo. Son útiles en una realización para inhibir la actividad TNFSF13b en un sujeto humano que padece un trastorno en el que la actividad hTNFSF13b es perjudicial. Están también comprendidos los ácidos nucleicos codificantes de estos anticuerpos, así como los vectores y células hospedadoras para expresarlos. Reivindicación 1: Un anticuerpo humano anti-hTNFSF13b que comprende un polipéptido seleccionado del grupo constituido por: a) polipéptido CDR1 de LCVR como muestra la SEC N° ID 4; b) polipéptido CDR2 de LCVR como muestra la SEC N° ID 6; c) polipéptido CDR3 de LCVR como muestra la SEC N° ID 8; d) polipéptido CDR1 de HCVR como muestra la SEC N° ID 12; e) polipéptido CDR2 de HCVR como muestra la SEC N° ID 14; y f) polipéptido CDR3 de HCVR como muestra la SEC N° ID 16.
ARP020103052A 2001-08-16 2002-08-13 Anticuerpos humanos antagonistas anti-htnfsf13b AR035119A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31280801P 2001-08-16 2001-08-16

Publications (1)

Publication Number Publication Date
AR035119A1 true AR035119A1 (es) 2004-04-14

Family

ID=23213094

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103052A AR035119A1 (es) 2001-08-16 2002-08-13 Anticuerpos humanos antagonistas anti-htnfsf13b

Country Status (26)

Country Link
US (4) US7317089B2 (es)
EP (2) EP1432735B1 (es)
JP (1) JP4012880B2 (es)
KR (1) KR100961299B1 (es)
CN (1) CN100497392C (es)
AR (1) AR035119A1 (es)
AU (2) AU2002322436C1 (es)
BR (1) BR0211630A (es)
CA (1) CA2452447C (es)
CO (1) CO5560617A2 (es)
DK (2) DK2348048T3 (es)
EA (1) EA009074B1 (es)
EC (1) ECSP044978A (es)
ES (2) ES2389834T3 (es)
HR (1) HRP20040147A2 (es)
HU (1) HU230006B1 (es)
IL (1) IL160373A0 (es)
MX (1) MXPA04001344A (es)
NO (1) NO20040603L (es)
NZ (1) NZ530657A (es)
PE (1) PE20030334A1 (es)
PL (1) PL212404B1 (es)
PT (2) PT1432735E (es)
UA (1) UA89017C2 (es)
WO (1) WO2003016468A2 (es)
ZA (1) ZA200401154B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
DE60143798D1 (de) 2000-06-16 2011-02-17 Cambridge Antibody Tech Immunspezifisch bindende antikörper gegen blys
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
JP4516719B2 (ja) 2001-05-11 2010-08-04 アムジエン・インコーポレーテツド Ｔａｌｌ−１と結合するペプチド及び関連分子
WO2006025345A1 (ja) * 2004-08-31 2006-03-09 Kowa Company, Ltd. 抗ヒトｂａｆｆ抗体
AU2006246721B2 (en) 2005-05-16 2012-12-13 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
NZ597082A (en) 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US8202698B2 (en) * 2005-11-08 2012-06-19 Biogen Idec Ma Inc. Methods of evaluating BAFF
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
CN101578113B (zh) 2007-01-11 2015-04-22 诺和诺德公司 抗-kir抗体、制剂及其应用
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
AR090626A1 (es) 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
SG10201913370PA (en) 2012-07-03 2020-03-30 Univ Washington Antibodies to tau
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
FI3677591T3 (fi) 2013-04-29 2023-04-03 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b
US10435474B2 (en) 2013-12-24 2019-10-08 Ossianix, Inc. Baff selective binding compounds and related methods
EA033604B1 (ru) * 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
TWI694836B (zh) * 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
EP3151857A4 (en) * 2014-06-03 2018-04-18 Merck Sharp & Dohme Corp. Anti-blys antibodies
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
EA037749B1 (ru) 2014-10-29 2021-05-18 Тева Фармасьютикалз Острэйлиа Пти Лтд ВАРИАНТЫ ИНТЕРФЕРОНА 2b
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
CN118515767B (zh) * 2024-07-23 2024-10-18 江苏双全生物医药科技有限公司 一种TNFSF13b抗体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6096878A (en) * 1993-05-10 2000-08-01 Japan Tobacco Inc. Human immunoglobulin VH gene segments and DNA fragments containing the same
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
EP0939804B2 (en) 1996-10-25 2011-06-15 Human Genome Sciences, Inc. NEUTROKINE alpha
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
AU9315298A (en) 1997-09-12 1999-03-29 Apotech S.A. Kay - a novel immune system protein
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US6787638B1 (en) 1998-12-02 2004-09-07 Applied Molecular Evolution, Inc. Tumor specific human monoclonal antibodies and methods of use
MXPA01007464A (es) 1999-01-25 2003-06-06 Apoxis Sa Baff, inhibidores del mismo y su uso en la modulacion de la respuesta de celula b.
NZ513290A (en) 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
DE60143798D1 (de) 2000-06-16 2011-02-17 Cambridge Antibody Tech Immunspezifisch bindende antikörper gegen blys

Also Published As

Publication number Publication date
HU230006B1 (en) 2015-04-28
US20100272735A1 (en) 2010-10-28
DK2348048T3 (en) 2014-12-15
IL160373A0 (en) 2004-07-25
HUP0500816A2 (en) 2007-07-30
PE20030334A1 (es) 2003-04-05
CA2452447A1 (en) 2003-02-27
HUP0500816A3 (en) 2010-01-28
US20080175841A1 (en) 2008-07-24
EP1432735A2 (en) 2004-06-30
CN1541224A (zh) 2004-10-27
EP1432735A4 (en) 2007-06-27
BR0211630A (pt) 2004-11-09
ES2526990T3 (es) 2015-01-19
HRP20040147A2 (en) 2004-10-31
EP2348048A1 (en) 2011-07-27
KR100961299B1 (ko) 2010-06-04
US7317089B2 (en) 2008-01-08
NZ530657A (en) 2006-02-24
CA2452447C (en) 2012-04-24
EP2348048B1 (en) 2014-11-19
US20050070694A1 (en) 2005-03-31
JP4012880B2 (ja) 2007-11-21
US20120195904A1 (en) 2012-08-02
PL212404B1 (pl) 2012-09-28
PT1432735E (pt) 2012-09-10
AU2008246261B2 (en) 2011-04-07
JP2005517384A (ja) 2005-06-16
US8173124B2 (en) 2012-05-08
DK1432735T3 (da) 2012-08-06
CO5560617A2 (es) 2005-09-30
ES2389834T3 (es) 2012-11-02
EA009074B1 (ru) 2007-10-26
AU2002322436B9 (en) 2009-04-09
KR20040030088A (ko) 2004-04-08
MXPA04001344A (es) 2004-05-05
WO2003016468A3 (en) 2003-11-20
CN100497392C (zh) 2009-06-10
US7728109B2 (en) 2010-06-01
AU2008246261A1 (en) 2008-12-11
AU2002322436C1 (en) 2011-09-01
ECSP044978A (es) 2004-03-23
EP1432735B1 (en) 2012-07-18
EA200400312A1 (ru) 2004-10-28
NO20040603L (no) 2004-05-14
AU2002322436B2 (en) 2008-12-04
PT2348048E (pt) 2015-02-04
ZA200401154B (en) 2005-06-22
PL370534A1 (en) 2005-05-30
UA89017C2 (uk) 2009-12-25
WO2003016468A2 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
AR035119A1 (es) Anticuerpos humanos antagonistas anti-htnfsf13b
US20190169303A1 (en) Humanized Anti-OX40 Antibodies and Uses Thereof
RU2425841C2 (ru) Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38
RU2016151645A (ru) Биспецифические гетеродимерные диантитела и их применение
ECSP21023271A (es) Anticuerpos cd20 con función del efector y afinidad de enlace al receptor fc mejoradas
AR046833A1 (es) Anticuerpos anti-interleuquina-10
SI2481753T1 (en) Anti-IL-17 antibodies
SA523440043B1 (ar) أجسام مضادة ضد cd3 إبسيلون جديدة
JP2018121657A5 (es)
RU2010136940A (ru) Антитела против альфа5-бета1 и их применение
PE20001316A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene
JP2012501669A5 (es)
RU2018133708A (ru) Антитела, обладающие специфичностью к btla, и их использование
RU2011144166A (ru) Способы применения антител к il-22 человека
RU2005132389A (ru) Гуманизированное анти-cd4 антитело с иммунодепрессивными свойствами
JP2015525208A5 (es)
KR900700134A (ko) Il-2 수용체-특이적 키메릭 항체
JP2012501670A5 (es)
RU2009110154A (ru) АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ
MX2025002112A (es) Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso
RU2011143903A (ru) Антитела к человеческому tweak и их применение
PE20030282A1 (es) Anticuerpos de interleucina-1- beta
DE69535562D1 (de) Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden
RU2005121669A (ru) Анти-nogo антитела ("11с7") и их фармацевтическое использование
RU2017122172A (ru) Антитела к IL-17C

Legal Events

Date Code Title Description
FA Abandonment or withdrawal